"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 2 | 11 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Simon L, Choudhary A, Ticku S, Barrow J, Tobey M. Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database. J Public Health Dent. 2022 09; 82(4):461-467.
-
Shirk SD, Ameral V, Kraus SW, Houchins J, Kelly M, Pugh K, Reilly E, Desai N. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A?Retrospective Chart Review. J Dual Diagn. 2021 Jul-Sep; 17(3):207-215.
-
Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA. COVID-19 and treating incarcerated populations for opioid use disorder. J Subst Abuse Treat. 2021 05; 124:108216.
-
Larochelle MR, Wakeman SE, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study. Med Care. 2020 10; 58(10):919-926.
-
Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.
-
Walley AY, Lodi S, Li Y, Bernson D, Babakhanlou-Chase H, Land T, Larochelle MR. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020 08; 115(8):1496-1508.
-
Bagley SM, Larochelle MR, Xuan Z, Wang N, Patel A, Bernson D, Silverstein M, Hadland SE, Land T, Samet JH, Walley AY. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. Ann Emerg Med. 2020 01; 75(1):29-38.
-
Bradley ES, Liss D, Carreiro SP, Brush DE, Babu K. Potential uses of naltrexone in emergency department patients with opioid use disorder. Clin Toxicol (Phila). 2019 Sep; 57(9):753-759.
-
Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486.
-
Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, Bowe T, Harris AHS. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 12; 95:43-47.